| Revision as of 22:48, 10 October 2011 editZéroBot (talk | contribs)704,777 editsm r2.7.1) (Robot: Adding pt:Associação sinvastatina/sitagliptina← Previous edit | Revision as of 11:28, 11 October 2011 edit undoEdgar181 (talk | contribs)Extended confirmed users196,325 editsm Disambiguate Merck to Merck & Co. using popupsNext edit → | ||
| Line 30: | Line 30: | ||
| '''Simvastatin/sitagliptin''' is a fixed-dose combination drug consisting of ] and ]. Sitagliptin is used to treat for ] and simvastatin is used to treat ].<ref>{{cite web | url = http://www.forbes.com/sites/larryhusten/2011/10/07/fda-approves-juvisync-combination-of-sitagliptin-and-simvastatin/ | title = FDA Approves Juvisync, Combination of Sitagliptin and Simvastatin | publisher = Forbes | date = October 7, 2011}}</ref> These two disorders commonly occur in patients at the same time, and have been typically treated with administration of these two drugs in separate tablets. The combination was approved in 2011 and is marketed as Juvisync by ]. | '''Simvastatin/sitagliptin''' is a fixed-dose combination drug consisting of ] and ]. Sitagliptin is used to treat for ] and simvastatin is used to treat ].<ref>{{cite web | url = http://www.forbes.com/sites/larryhusten/2011/10/07/fda-approves-juvisync-combination-of-sitagliptin-and-simvastatin/ | title = FDA Approves Juvisync, Combination of Sitagliptin and Simvastatin | publisher = Forbes | date = October 7, 2011}}</ref> These two disorders commonly occur in patients at the same time, and have been typically treated with administration of these two drugs in separate tablets. The combination was approved in 2011 and is marketed as Juvisync by ]. | ||
| ==References== | ==References== | ||
Revision as of 11:28, 11 October 2011
Pharmaceutical compound| Combination of | |
|---|---|
| Simvastatin | hypolipidemic statin |
| Sitagliptin | antidiabetic DPP-4 inhibitor |
| Clinical data | |
| Trade names | Juvisync |
Simvastatin/sitagliptin is a fixed-dose combination drug consisting of sitagliptin and simvastatin. Sitagliptin is used to treat for type 2 diabetes and simvastatin is used to treat hypercholesterolemia. These two disorders commonly occur in patients at the same time, and have been typically treated with administration of these two drugs in separate tablets. The combination was approved in 2011 and is marketed as Juvisync by Merck.
References
- "FDA Approves Juvisync, Combination of Sitagliptin and Simvastatin". Forbes. October 7, 2011.
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |